MedTrace Logo

Amonafide in Combination With Cytarabine in Secondary AML

NCT00273884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2007-02-19

No results posted yet for this study

Summary

This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.

Conditions

Interventions

DRUG

Amonafide L-Malate

DRUG

Cytarabine

Sponsors & Collaborators

  • Xanthus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Steven Allen, MD · North Shore Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Completion
2009-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00273884 on ClinicalTrials.gov